Korro Bio (KRRO) Operating Expenses (2018 - 2026)

Korro Bio (KRRO) has reported Operating Expenses for 9 consecutive years, with $20.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 29.84% year-over-year to $20.1 million; the trailing twelve-month figure through Jun 2026 stood at $112.6 million (up 7.37% YoY), and the FY2025 full-year result was $128.2 million, up 36.17% from the prior year.
• Operating Expenses fell to $20.1 million in Q2 2026 per KRRO's latest filing, from $20.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $51.7 million in Q4 2025 and bottomed at -$5.8 million in Q4 2022.
• Historically, Operating Expenses has averaged $22.6 million across 5 years, with a median of $21.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 127.19% in 2022, then surged 563.03% in 2023.
• Over 5 years, Operating Expenses stood at -$5.8 million in 2022, then soared by 563.03% to $26.9 million in 2023, then declined by 5.88% to $25.3 million in 2024, then soared by 104.21% to $51.7 million in 2025, then sank by 61.09% to $20.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $20.1 million, $20.4 million, and $51.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.